A therapeutic dendritic cell-based vaccine for HIV-1 infection. - Wikidata - awgldk - TriplyDB

A therapeutic dendritic cell-based vaccine for HIV-1 infection.

A therapeutic dendritic cell-based vaccine for HIV-1 infection.

http://www.wikidata.org/entity/Q34764392

about

Current Advances in Virus-Like Particles as a Vaccination Approach against HIV Infection Cytokine production and dysregulation in HIV pathogenesis: lessons for development of therapeutics and vaccines Can immunotherapy be useful as a "functional cure" for infection with Human Immunodeficiency Virus-1?Synthetic DNA vaccine strategies against persistent viral infections Dendritic Cell-Based Immunotherapies to Fight HIV: How Far from a Success Story? A Systematic Review and Meta-Analysis An old enzyme for current needs: adenosine deaminase and a dendritic cell vaccine for HIV.DermaVir: a plasmid DNA-based nanomedicine therapeutic vaccine for the treatment of HIV/AIDS.Controlling the HIV/AIDS epidemic: current status and global challenges Generation and characterization of a defective HIV-1 Virus as an immunogen for a therapeutic vaccine.Dendritic cells exposed to MVA-based HIV-1 vaccine induce highly functional HIV-1-specific CD8(+) T cell responses in HIV-1-infected individuals.Novel exosome-targeted T-cell-based vaccine counteracts T-cell anergy and converts CTL exhaustion in chronic infection via CD40L signaling through the mTORC1 pathway Requirements for empirical immunogenicity trials, rather than structure-based design, for developing an effective HIV vaccine.Immune interventions in HIV infection.Microfluidic squeezing for intracellular antigen loading in polyclonal B-cells as cellular vaccines Adenosine deaminase enhances the immunogenicity of human dendritic cells from healthy and HIV-infected individuals.BDCA1-positive dendritic cells (DCs) represent a unique human myeloid DC subset that induces innate and adaptive immune responses to Staphylococcus aureus Infection.Towards an HIV cure: a global scientific strategy A dendritic cell-based vaccine elicits T cell responses associated with control of HIV-1 replication.Autologous aldrithiol-2-inactivated HIV-1 combined with polyinosinic-polycytidylic acid-poly-L-lysine carboxymethylcellulose as a vaccine platform for therapeutic dendritic cell immunotherapy Exploring the potential of monoclonal antibody therapeutics for HIV-1 eradication.Dendritic cell-based immunization ameliorates pulmonary infection with highly virulent Cryptococcus gattii Effects on innate immunity of a therapeutic dendritic cell-based vaccine for HIV-1 infection Effect of therapeutic HIV recombinant poxvirus vaccines on the size of the resting CD4+ T-cell latent HIV reservoir Expansion of polyfunctional HIV-specific T cells upon stimulation with mRNA electroporated dendritic cells in the presence of immunomodulatory drugs A STATus report on DC development.Barriers to a cure for HIV: new ways to target and eradicate HIV-1 reservoirs Safety, tolerability, and immunogenicity of repeated doses of dermavir, a candidate therapeutic HIV vaccine, in HIV-infected patients receiving combination antiretroviral therapy: results of the ACTG 5176 trial.Suppression of colitis by adoptive transfer of helminth antigen-treated dendritic cells requires interleukin-4 receptor-α signaling Combined approaches for HIV cure.Dendritic cells in the pathogenesis and treatment of human diseases: a Janus Bifrons?Therapeutic vaccines against HIV infection.Optimizing dendritic cell-based immunotherapy: tackling the complexity of different arms of the immune system.Enhancing immunogenicity and cross-reactivity of HIV-1 antigens by in vivo targeting to dendritic cells.Attacking the HIV reservoir from the immune and viral perspective.Dendritic cell dysregulation during HIV-1 infection.Dendritic cell based vaccines for HIV infection: the way ahead.A cure for AIDS: a matter of timing?Dendritic cell-based approaches in the fight against diseases.Future considerations for dendritic cell immunotherapy against chronic viral infections.Dendrimers as nonviral vectors in dendritic cell-based immunotherapies against human immunodeficiency virus: steps toward their clinical evaluation.

P2860

Q26775082-2027D1FA-A2D6-4730-BEFE-840F71419C4E Q26827712-194B6B1E-C879-4BA4-A6CD-62C61AEACAAC Q26865388-938F654D-9A0E-4CA9-936F-85055B29C708 Q27016078-9B29BD54-D27A-4F67-9FA0-23B5D34CACD3 Q28070121-18C6806C-4ECE-42DB-9890-BC85230DF0C7 Q30407263-C4BCB832-3ACA-4F7C-A296-B1A7C3836504 Q30408029-57CCBFFC-6EEC-4663-AC52-1BBDBFB3709F Q30420558-88D56C9F-351C-48E5-A80A-1C6F5D17AE87 Q31106756-20CD3868-5CCB-42A9-B86F-F921E829A22B Q33916776-2051D07D-F5AC-4E89-B254-233D8FE61E37 Q33920141-1B12581A-4F5F-485D-9A9B-F520E4C447FF Q34225659-93D19D8C-D74E-48B1-AEAC-14CA34BBB074 Q34351326-731C9CAB-71C1-4EFB-BED5-D2A15D396FC8 Q34477358-93EA06A4-42EE-4E20-9521-E51C222E80B6 Q34512293-0086B4EF-9B23-42FA-811E-D098A1FB93C2 Q34596173-CB57958D-3438-42FA-A700-89CBA4E7954A Q34640562-77B007D6-55C6-46EA-8041-6C967A9D314A Q34646987-7DD6E482-119A-4F3B-9303-FB7DBEB87C60 Q34749218-55CBE572-33EF-4384-9134-D6E787C04D8C Q34869927-C20A5151-F8D9-4FBE-B6DF-531E322A39F2 Q35187555-443DC0AB-7771-40B4-8742-2B49E8FF06B3 Q35731394-B9893144-FC96-49D9-8EBE-665A125954CD Q35857687-971C6592-9710-4695-B46F-605AA72B99AD Q36154837-484EBEB1-BE80-4931-88C6-AAF95408ECF3 Q36188887-79701985-6453-4DAD-A5EE-1F8DFC47DD2F Q37273652-11CC0945-655B-4B3B-8DAA-148431F69104 Q37381097-7E5A1DFD-6F7B-4143-AC39-4B02F5412647 Q37589645-9B386DB7-7EEA-41B8-B3B8-E04644A8F5DD Q37664312-C03EEC94-45D1-48FA-A6CD-6B2AAA77F930 Q37945301-15A33AD8-C8D2-4A42-B1AD-F3AADEFD38EF Q38013505-BCB3D3C6-B916-4C17-8905-E08CFA67D660 Q38031222-DB2E8C6B-8065-4CA0-BA46-0582B6E0C9D6 Q38059499-A7E8E046-CF7E-4B22-B3C2-22A7CBD83C1B Q38067646-2758108C-2641-41CD-A150-960F287040E7 Q38114911-83223520-C88F-4498-9EA9-F641BB7D7CE7 Q38126373-982C5396-C22B-466E-BFB1-53884991DCD2 Q38165451-8E5336DF-A2CA-49B0-9AC5-9ED1D431B7DA Q38195040-55CABA19-D12E-4DF3-92C4-60CA0EC2E1C4 Q38204769-18F7B11B-2E79-4EAD-B304-8D95D090C431 Q38296086-9A063DE8-5BF6-4BD5-8BA2-E5E2C89A4642

P2860

A therapeutic dendritic cell-based vaccine for HIV-1 infection.

http://www.wikidata.org/entity/Q34764392

description

2011 nî lūn-bûn

@nan

2011 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

A therapeutic dendritic cell-based vaccine for HIV-1 infection.

@ast

A therapeutic dendritic cell-based vaccine for HIV-1 infection.

@en

A therapeutic dendritic cell-based vaccine for HIV-1 infection.

@nl

type

label

A therapeutic dendritic cell-based vaccine for HIV-1 infection.

@ast

A therapeutic dendritic cell-based vaccine for HIV-1 infection.

@en

A therapeutic dendritic cell-based vaccine for HIV-1 infection.

@nl

prefLabel

A therapeutic dendritic cell-based vaccine for HIV-1 infection.

@ast

A therapeutic dendritic cell-based vaccine for HIV-1 infection.

@en

A therapeutic dendritic cell-based vaccine for HIV-1 infection.

@nl

P1433

Q34764392-6E431B2B-73F4-451B-83E9-64BCF93550B3

P1476

Q34764392-AAE86BEB-47EB-4E74-9108-9EF538399ED7

P2093

Q34764392-0947562C-E6C1-44B5-849C-3ACC192A5EC2

Q34764392-0CAAE9F4-6E1E-4BA6-A4BB-B8552EFBB48A

Q34764392-743FF01A-625A-443F-8D60-AC18D8AB8968

Q34764392-9FD24458-D8B1-4ADC-B17A-66CBAD6C5A48

Q34764392-ADEDDB45-FAFD-4D39-A69B-20DD409AE5F2

Q34764392-AF748833-17D6-4880-9D34-B3F31C9D6451

Q34764392-CC95B810-A6D9-487F-9654-15486AFEA901

Q34764392-EC653BC0-E63A-4189-A29E-0535E255434D

Q34764392-FAE58442-2F80-4882-A88E-AACA74EAD362

Q34764392-FC5A8CFB-C39E-42F7-93F9-CE74311AB3E3

P2860

Q34764392-3DBF01CA-8FB8-426E-8B1C-A8ABFEEEC012

Q34764392-4CCE717E-B62C-4A1F-B96B-7A134AB5647B

Q34764392-4CD845D5-A619-4DE7-A529-05224CF1908C

Q34764392-4F79401B-9376-458B-A873-490DAE37D3F8

Q34764392-5E793F60-2287-4E05-B17D-645C07C2D59C

Q34764392-88B94281-2125-4214-A1A2-22C6925382D9

Q34764392-8C408B92-3701-490E-B628-30D18BE2DC9A

Q34764392-95EF19B1-6440-4244-A459-9D66528DC127

Q34764392-AD68E7BD-96BC-4632-84C4-B6B0F3C63ACA

Q34764392-B1EFE288-83F5-4341-A132-022924DF8DB4

P304

Q34764392-C9CB467E-9F6A-4A97-9AED-619280FEA15A

P31

Q34764392-F43D35D5-BC8F-4DDF-96AF-073A0D542049

P356

Q34764392-7B2BB45A-0924-4AEB-A382-C32F5643E7E1

P407

Q34764392-B9CD9600-D32A-48AF-86A8-8700AFC6B7D5

P433

Q34764392-58B1EAA8-45F8-430A-A48C-5AC6A859846E

P478

Q34764392-BB7FDD64-2F4F-4843-991C-D2A4D776B12D

P50

Q34764392-17D7C5A2-7823-4E07-B68F-AD3DDA01EBCE

Q34764392-42D01CB1-47F5-4B55-BC7A-76C458027ECA

Q34764392-62912557-E485-4840-97F6-92870526BF75

Q34764392-9FEA7B38-BDFA-48B1-BFC2-8B1325635814

Q34764392-C5CCC230-CEFA-4D9C-9798-38496E5FC1D2

Q34764392-C651EFE2-2D36-409B-ABE0-A154FEF690CF

Q34764392-CB7B7867-8B5B-41C6-8151-5D8FD985A84F

Q34764392-E4DE2996-5C90-46AE-9C93-486919DCCF47

P577

Q34764392-EA411FAC-7337-4A4D-B0B6-988D082619B5

P5875

Q34764392-EF86FF96-6B40-45CF-BEE3-6857E3BE4D72

P698

Q34764392-A4840F01-7B4D-4BCC-B0A2-30E571CFC972

P932

Q34764392-6C973010-EE5D-4F71-8393-A492B32569E0

P356

P1433

The Journal of Infectious Diseases

P1476

A therapeutic dendritic cell-based vaccine for HIV-1 infection.

@en

P2093

Cristina Gil

http://www.w3.org/2001/XMLSchema#string

DCV2/MANON07- AIDS Vaccine Research Objective Study Group

http://www.w3.org/2001/XMLSchema#string

Jeff Lifson

http://www.w3.org/2001/XMLSchema#string

Joan Romeu

http://www.w3.org/2001/XMLSchema#string

Josep M Gatell

http://www.w3.org/2001/XMLSchema#string

Judith Dalmau

http://www.w3.org/2001/XMLSchema#string

Lambert Assoumou

http://www.w3.org/2001/XMLSchema#string

Montserrat Plana

http://www.w3.org/2001/XMLSchema#string

Nuria González

http://www.w3.org/2001/XMLSchema#string

Teresa Gallart

http://www.w3.org/2001/XMLSchema#string

P2860

Standardized peripheral blood mononuclear cell culture assay for determination of drug susceptibilities of clinical human immunodeficiency virus type 1 isolates. The RV-43 Study Group, the AIDS Clinical Trials Group Virology Committee Resistance Wor

International network for comparison of HIV neutralization assays: the NeutNet report.

Increased alpha-defensins 1-3 production by dendritic cells in HIV-infected individuals is associated with slower disease progression

Immunologic activity and safety of autologous HIV RNA-electroporated dendritic cells in HIV-1 infected patients receiving antiretroviral therapy

A randomized therapeutic vaccine trial of canarypox-HIV-pulsed dendritic cells vs. canarypox-HIV alone in HIV-1-infected patients on antiretroviral therapy

In vitro human immunodeficiency virus eradication by autologous CD8(+) T cells expanded with inactivated-virus-pulsed dendritic cells.

Infectious and whole inactivated simian immunodeficiency viruses interact similarly with primate dendritic cells (DCs): differential intracellular fate of virions in mature and immature DCs

Therapeutic immunization with human immunodeficiency virus type 1 (HIV-1) peptide-loaded dendritic cells is safe and induces immunogenicity in HIV-1-infected individuals.

Impact of therapeutic immunization on HIV-1 viremia after discontinuation of antiretroviral therapy initiated during acute infection.

MHC-I-restricted presentation of HIV-1 virion antigens without viral replication.

P304

473-478

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/INFDIS/JIQ077

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

203

http://www.w3.org/2001/XMLSchema#string

P50

Brigitte Autran

Bonaventura Clotet Sala

Dominique Costagliola

Javier Martinez-Picado

P577

2011-01-13T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

49753835

http://www.w3.org/2001/XMLSchema#string

P698

21233310

http://www.w3.org/2001/XMLSchema#string

P932

3071229

http://www.w3.org/2001/XMLSchema#string